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Endothelial cells can release substances which profoundly affect vascular tone and platelet function. The
inhibitory substances include endothelium-derived relaxing factor (EDRF or nitric oxide), prostacyclin and
probably an endothelium-derived hyperpolarizing factor. Endothelin is a potent vasoconstrictor peptide
released from endothelial cells. Under certain conditions, the endothelium can also produce angiolensin II,
thromboxane A, and a cyclooxygenase-dependent endothelium-derived contracting factor. In normal arteries,
the effects of EDRF appear to dominate. In diseased arteries, the release and action of EDRF is impaired and
that of endothelium-derived contracting factors is increased. Hyperlipidaemia, atherosclerosis and hyperten-
sion reduce endothelium-dependent relaxations. Hypoxia inhibits the release of EDRF and prolonged ischae-
mia severely impairs the response. Regenerated endothelium at sites of mechanical injury exhibits selective
defects in response to aggregating platelets. The more effective release of EDRF in arterial compared with
venous bypass grafts further suggests an involvement of the factor in preventing vascular occlusion. Thera-
peutic interventions with specific drugs and diets can augment the impaired endothelium-dependent relaxation
of diseased arteries. Thus, functional changes of the endothelium in coronary artery disease may be an
important factor in the development of vasospasm, ischaemia and thrombosis.
Introduction modulate the degree of myocardial ischaemia161. Re-
cent research indicates that the endothelium has a
Reduced blood flow to the myocardium is the com-
 p r o t e c t i V e function in the circulation by preventing
mon feature of ischaemic heart disease"'. Ischaemia
 v a s o s p a s m a n d t h r ombus formation. This review
may develop due to vascular thrombosis, stenosis
 s u m m a r i z e s c u r r e n t knowledge on the physiologi-
and/or vasospasm^1 . In most instances, the major
 ral i m p o r t a n c e o f endothelium-derived relaxing
event in myocardial infarction is occlusion of one
 a n d c o n t r a c t i n g f a c t o r s a n d t h e i r potential role in
or more large epicardial coronary arteries. Plaque
 c o r o n a r y a r t e r y disease171,
fissuring, coronary vasospasm and thrombus for-
mation are crucial events in unstable angina and
evolving myocardial infarction. Similarly, increased Endothelium-derived vasoacrive substances
platelet vessel wall interactions with platelet
deposition play an important role in coronary by- ENDOTHELIUM-DERIVED RELAXING FACTORS
pass graft occlusion'51. In exercise-induced angina, Prostacyclin (PGI2) is the major cyclooxygenase
vascular tone of the diseased arterial segment can product of the blood vessel wall181. Endothelial cells
produce 10-20 times more PGI2 than do vascular
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Figure 1 Endothelium-derived vasoactive substances. AA = Arachidonic acid;
ACE = angiotensin converting enzyme; ATG = angiotensinogen; ACh = acetylcholine;
ATI/II = angiotensin I/II; cAMP/cGMP = cyclic adenosine/guanosine monophosphate;
EDCF = endothelium-derived constricting factor(s); EDHF = endothelium-derived
hyperpolarizing factor; NO = nitric oxide; PGI2 = prostacyclin (modified from ref. 7).
luminal release of the prostanoid, but its production
is not restricted to these cells. PGI2 is a potent in-
hibitor of platelet aggregation and a vasodilator of
coronary arteries. Its mechanism of action involves
increases in intracellular cyclic adenosine 3',5'-
monophosphate (cyclic AMP). Platelet-inhibitor
drugs, such as aspirin, which inhibit cyclooxyge-
nase, reduce vascular prostacyclin production.
Furchgott and Zawadzki''1 first demonstrated
that the relaxation in arteries induced by acetylcho-
line is endothelium-dependent and mediated by a
diffusible substance with a half-life of a few seconds
which they named endothelium-derived relaxing fac-
tor (EDRF, Fig. 2). Haemoglobin, oxygen-derived
free radicals and antioxidants are potent inhibitors
of EDRF110"121. The factor is a potent vasodilator
and inhibitor of platelet adhesion and aggregation
(Fig. 3)"3"151. Subthreshold concentrations of either
EDRF or PGI2 enhance the vascular and antiaggre-
gatory effects of the other substance113161. In the cor-
onary circulation, EDRF preferentially increases
subendocardial blood flow1"1. The action of EDRF
on vascular smooth muscle involves activation of
soluble guanylate cyclase and in turn increases in
intracellular levels of cyclic guanosine 3',5'-mono-
phosphate (cyclic GMP) (Fig. I)"81. Substances
interfering with the production of cyclic GMP
(methylene blue, LY 83583) inhibit endothelium-
dependent relaxations. Endothelial cells in culture
release nitric oxide after stimulation with brady-
kinin1"1. Nitric oxide has a similar half-life and
mode of action to EDRF and the amounts released
from endothelial cells appear sufficient to explain
the biological activity of the factor in vascular
tissues and in platelets'"1. L-arginine is the precursor
substance from which nitric oxide is cleaved in
endothelial cells'201. Thus, the endothelium pro-
duces an endogenous nitrate which causes relaxa-
tion of vascular smooth muscle and inhibition of
platelet function. EDRF is released in response to
flow (shear stress), platelet-derived products (i.e.
adenosine diphosphate, thrombin, serotonin) and
hormones and autocoids (i.e. bradykinin, hista-
mine, noradrenalin, substance P and vasopres-
sin)'712-21-22"241. Aggregating platelets release enough
adenine nucleotides and serotonin to induce endo-
thelium-dependent relaxations in isolated blood
vessels'231. Adenosine diphosphate is the main
mediator of the response to aggregating platelets in
human coronary arteries, while the effects of sero-
tonin and thromboxane A2 are endothelium-
independent (Fig. 3)1241. Several platelet-derived
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Figure 2 Endothelium-dependent relaxation in response to acetyl-
choline in a human internal mammary artery (NE; original record-
ing). The relaxation in response to acetylcholine can be reversed by
haemoglobin (Hb 10"' M; upper panel) (from ref. 10, by permisson).
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Figure 3 Release of endothelium-derived relaxing factor (EDRF) and
prostacyclin (PGI,) by platelet-derived substances such as thrombin, adeno-
sine tri- and diphosphate (ATP/ADP) and by histamine (HST) in human
arteries. EDRF and PGI2 cause vascular relaxation and inhibit platelet
function. — = uncertain (modified from ref. 7).
products stimulate the endothelial production of
EDRF as well as that of PGI2 and tissue plasmino-
gen activator171. Thus, at sites where platelets are
activated, potent vasodilators and inhibitors of
platelet function are released which may provide a
protective mechanism against vasospasm, ischae-
mia and thrombus formation.
In addition, the endothelium must release an
endothelium-derived hyperpolarizingfactor (EDHF;
Fig. I)1251. The sodium-potassium -.ATPase in-
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hibitor, ouabain, reduces endothelium-dependent
relaxations to acetylcholine in the canine femoral
artery261. Acetylcholine causes endothelium-depen-
dent increases in membrane potential of vascular
smooth muscle cells which can be blocked by
ouabain1271. Exogenous nitric oxide does not hyper-
polarize vascular smooth muscle cells nor does
haemoglobin prevent the increase in membrane
potential in response to acetylcholine, indicating
that an endothelium-derived substance other than
EDRF must be involved'28'. Although the physio-
logical role of this factor is unclear yet, hyper-
polarization of vascular smooth muscle cells may
contribute to the sustained phase of endothelium-
dependent relaxations and it may render the cells
less responsive to contractile stimuli.
ENDOTHELIUM-DERIVED CONTRACTING FACTOR(S)
Under certain conditions, the endothelium can
mediate vasoconstriction (Fig. I)'71. Yanasigawa et
a/.'291 have recently described the vasoconstrictor
peptide endothelin which is released from endo-
thelial cells in culture. Endotheliri is the most potent
endogenous vasoconstrictor substance known, with
a half-maximal effective concentration 1-2 orders
of magnitude lower than that of any other known
cardiovascular hormone. Thrombin and the cal-
cium ionophore, A23187, express preproendothelin
messenger RNA in cultured endothelial cells and in
large arteries in situ. The peptide binds to specific
membrane receptors of vascular smooth muscle
cells where it induces increases in intracellular
calcium and in turn long-lasting contractions'301.
Whether the endothelium-derived contracting fac-
tor released under hypoxic conditions in the canine
coronary artery is endothelin or an as yet unknown
substance is uncertain'311. In addition, the endo-
thelium and vascular wall possess an independent
renin-angiotensin system which may provide high
local concentrations of the potent vasoconstrictor
angiotensin //32). Histamine, thromboxane A2 and
another cyclooxygenase-dependent endothelium-
derived contracting factor can also be produced in
endothelial cells of certain vascular beds (Fig. I)171.
Thus, the endothelium profoundly affects vascu-
lar smooth muscle tone and platelet function by the
release of endothelium-derived relaxing and con-
tracting factors (Fig. 1). Under physiological con-
ditions, endothelium-derived relaxing factors most
likely dominate. Indeed, in normal human conduit
arteries and in mesenteric resistance arteries of the
rat, EDRF overrides endothelin'33-341. An alteration
of the release of endothelium-derived relaxing
and/or contracting factors under pathological
conditions, on the other hand, may be important in
the pathophysiology of cardiovascular disease.
Cardiovascular risk factors and the endothelium
Risk factors for coronary artery disease such as
hyperlipidaemia, atherosclerosis and hypertension
impair endothelium-dependent relaxations in ex-
perimental animals and in human coronary arter-
ies. In the rabbit aorta, low-density lipoprotein
(LDL), but not high-density lipoprotein (HDL),
inhibits endothelium-dependent relaxations in re-
sponse to acetylcholine1351. The inhibitory concen-
tration of the lipoprotein corresponds to that found
in plasma of patients with severe hyperlipidaemia.
In addition, LDL and atherosclerosis inhibit vascu-
lar prostacyclin production136'. In atherosclerotic
arteries, including the human coronary artery,
endothelium-dependent relaxations in response to
acetylcholine, adenosine diphosphate, bradykinin,
substance P and aggregating platelets are reduced
(Fig. 4)I24-3M|] Selective infusion of acetylcholine
into the left anterior descending coronary artery
causes paradoxical contractions in patients with
coronary artery disease and in transplant recipients
(Fig. 5)(4O). A reduced release of EDRF, structural
changes of the intima and media, and — at least in
the porcine coronary artery — the release of an
endothelium-derived contracting factor are re-
sponsible for these changes in atherosclerotic
arteries'3'41'. In experimental hypertension,
endothelium-dependent relaxations are reduced in
most vascular beds (Fig. 6)17-42-43'. In the carotid
artery of hypertensive rats, endothelium-dependent
relaxations in response to acetylcholine and adeno-
sine diphosphate are blunted'42'. This may be
important in the development of stroke, which is the
majorcardiovascularcomplicationoftheseanimals.
In the canine coronary circulation, acute hyperten-
sion selectively and persistently attenuates endo-
thelium-dependent responses to serotonin.'431
Contractions in response to endothelin areenhanced
in renal, but not in mesenteric resistance arteries of
hypertensive rats'33341. Endothelin almost com-
pletely inhibits the effects of EDRF in hypertensive,
but not in normotensive arteries.'33'
Ischaemia, myocardial infarction and the
endothelium
In vitro, hypoxia and ischaemia inhibit the pro-
duction and release of endothelium-derived relax-
ing factor and — at least in the canine coronary
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Figure 4 Endothelium-dependent relaxations in response to acetylcholine, substance P, and histamine in
normal (O) and atherosclerotic ( • ) human coronary arteries. Note the impaired response in diseased
arteries ( • ) . 'Denotes statistically significant difference (/><005) (modified from ref. 39, by permission).
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Figure 5 Effects of intracoronary infusion of acetylcholine on the diameter of
the left anterior descending coronary artery in (a) patients with coronary artery
disease and (b) normal subjects. Note the paradoxical contractions of the dis-
eased arteries. Ach = acetylcholine; C1, C2, C3 = control period, vehicle control
and repeated control, respectively; TNG = nitroglycerin (modified from ref. 40,
by permission). • — • =prestenotic segment; O — O =stenotic segment;
• • = normal vessel.
artery—trigger the release of an endothelium-
derived contracting factor131451. In some vascular
beds, endothelial prostaglandins contribute to
hypoxic vasodilatation'46'. After experimental
myocardial infarction with delayed reperfusion,
endothelium-dependent relaxations of the canine
coronary artery to acetylcholine and thrombin are
severely impaired and the contractions induced by
the enzyme are enhanced147'481. Pretreatment of the
animals with the calcium-channel antagonist, vera-
pamil, partially restores endothelium-dependent
relaxations, indicating that accumulation of intra-
cellular calcium during ischaemia is involved in
endothelial cell injury. In addition to the ischaemic
injury, reperfusion itself may traumatize the endo-
thelium1491. Reperfusion injury most likely is
related to the formation of free radicals and/or
enhanced neutrophil-endothelial interactions'491.
Indeed, oxygen-derived free radicals destroy EDRF
and they are cytotoxic1"1. Reperfusion injury and
the decreased release of EDRF associated with it
can at least in part be prevented by intracoronary
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Figure 6 Effect of antihypertcnsive therapy on endo-
theliutn-dependent relaxations in response to thrombin
IUml"1 in the aorta of Dahl salt-sensitive (left) and salt-
resistant (right) rats on a diet containing either 8% or 0 1 %
NaCl. Note the normalization of the response to thrombin in
salt-sensitive rats on 8% NaCl (i.e. hypertensive group)
during antihypertensive therapy (AHD) (from ref. 78, by per-
mission of the American Heart Association). Q = 8 % NaCl.
K = 0-l% NaCl; 3 = 8 % NaCl + AHD (2 weeks); 3 = 8%
NaCl +AHD(8weeks).
infusion of a perfluorochemical'491. Reperfusion-
induced endothelial dysfunction appears to per-
sist as does that after mechanical injury (see
section on endothelium dysfunction and vascular
occlusion)1501.
Endothelium-depeudent responses and coronary
vasospasm
Coronary artery spasm can contribute to myc-
cardial ischaemia'2*51-52'. A local dysfunction of the
endothelium may play a role in that phenomenon.
Indeed, coronary spasm can be provoked by a var-
iety of substances which release EDRF in isolated
arteries, such as acetylcholine, methacholine, hista-
mine, serotonin and ergonovine153"541. All these
substances exert endothelium-dependent inhibitory
and direct excitatory effects. Thus, a local loss of
EDRF and/or the release of an endothelium-deri ved
contracting factor may precipitate coronary spasm
in response to these substances. Intracoronary
acetylcholine produces paradoxical contractions in
patients with coronary artery disease (Fig. 5)1*01.
Histamine causes vasodilatation when infused into
the normal coronary circulation and endothelium-
dependent relaxations in isolated human ar-
teries155"571. Removal of the endothelium unmasks
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Figure 7 Endothelium-dependent relaxations to aggregat-
ing platelets in porcine coronary arteries 1 and 4 weeks after
deendothelialization with a balloon catheter. Note the
impaired relaxations four weeks after the intervention.
• = LAD; D = LCX; ( + ) = with endothelium; ( - ) = without
endothelium; * = statistically significant difference from
control (/><005); n = 6 in each group (from ref. 63, by
permission of the American Heart Association).
contractions in response to the amine. In the pig,
coronary vasospasm can be provoked by histamine
at sites of previous endothelial denudation in
conjunction with an atherogenic diet'581. A local
increase in adventitial mast cells, which are a major
source of histamine, has been documented in a
patient with coronary spasm'591. Coronary arteries
of patients with coronary artery disease contain
increased amounts of histamine and exert enhanced
contractions in response to the amine1601. Thus, at
sites of previous endothelial injury and dysfunction,
the direct vasoconstrictor effects of the amine may
predominate and precipitate vasospasm. However,
histamine is effective in provoking vasospasm only
in some, but not all patients with variant angina1541.
Consistent with platelet activation, coronary
sinus thromboxane B2 levels are elevated during
attacks of variant angina'61'. Thus, platelet-derived
substances such as serotonin, adenosine diphos-
phate and thrombin are abundantly present and
may contribute to the contraction of the diseased
arterial segment. In vivo endothelial denudation
of the coronary artery leads to spontaneous con-
traction and enhanced vasoconstrictor responses to
serotonirf62-63\ Porcine coronary arteries with
regenerated endothelium after balloon injury exhi-
bit a selective and persistent defect of endothelium-
dependent relaxations in response to serotonin and
aggregating platelets (Fig. 7)1631. In addition,
contractions induced by serotonin are enhanced in
pig coronary artery rings with regenerated endo-
thelium, suggesting the release of an endothelium-
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derived contracting factor. In man, the defect
would have to involve a platelet-derived mediator
other than serotonin, since the monoamine does not
induce the release of EDRF in human arteries'24'571.
Endothelium dysfunction and vascular occlusion
In normal blood vessels, the release of EDRF,
prostacyclin and tissue plasminogen activator from
endothelial cells may help prevent vasospasm and
thrombus formation. In atherosclerotic arteries,
platelets become activated indicating an increased
platelet-vessel wall interaction. Coronary sinus
blood from patients with coronary artery disease
exhibits vasoconstrictor activity in isolated arteries
and this effect is related to the severity of the
disease(641._Endothelial dysfunction may be a crucial
factor allowing platelet deposition and activation,
release of platelet-derived substances and, in turn,
decrease in local blood flow.
In man, increased platelet-vessel wall inter-
actions are particularly important in the patho-
physiology of unstable angina. Coronary angios-
copy in patients with this syndrome reveals
complex plaques with intimal haemorrhage and
thrombi, while these findings are lacking in
patients with stable angina'651. At the site of intra-
vascular haemorrhage, free haemoglobin may
inhibit EDRF. In the dog, thromboxane A2
receptor antagonists inhibit cyclic variations in
flow as well as platelet deposition in stenosed
coronary arteries'661. This indicates that there is a
continuous build-up and flush-away of platelet
clots interfering with local blood flow. Endo-
thelial injury of a large conduit artery provokes
collateral arterial vasoconstriction mediated by
serotonin and thromboxane A2 released from
platelets adhering and aggregating at the site of
endothelial denudation'671. Substances interfering
with either the production or the vascular effects
of platelet-derived products (i.e. cyclooxygenase
inhibitors, calcium-channel antagonists), on the
other hand, improve symptoms or the incidence
of subsequent myocardial infarction in patients
with unstable angina'68"701. This indicates that
altered intimal surface characteristics, most likely
a decreased release of EDRF and PGI2 at sites of
atherosclerosis and intimal bleeding, are associ-
ated with platelet activation and deposition and
the release of platelet-derived substances. All
these events favour vasoconstriction of epicardial
coronary arteries as well as of collaterals, and
thrombus formation.
Arterial and venous coronary bypass vessels may
provide a model to study possible mechanisms
involved in vascular occlusion in vitro in human
tissue. As a graft, the internal mammary artery has
remarkedly higher patency rate than the saphenous
vein. Since this difference persists, if grafts supply-
ing the same vascular bed (i.e. left anterior descend-
ing coronary artery) are compared, this indicates
that different biological properties of arterial and
venous bypass vessels must be involved17'1. In
mammary arteries, acetylcholine induces complete
endothelium-dependent relaxations and induces a
marked rise in cyclic GMP levels in vascular smooth
muscle cells (Fig. 2)'10-721. The response evoked by
the muscarinic agonist is unaffected by indometha-
cin, but inhibited by methylene blue and haemo-
globin, identifying EDRF as the mediator. In
contrast to the mammary artery, saphenous veins
exhibit much weaker endothelium-dependent relax-
ations in response to acetylcholine (Fig. 8)1101.
However, veins can respond to nitrovasodilators
and exogenous nitric oxide as well as to arterial
EDRF transferred from a mammary artery seg-
ment with endothelium1101. Indeed, the sensitivity to
nitric oxide is enhanced in human veins compared
with arteries indicating a reduced release of EDRF
in the former'721. This may also explain why nitrates
used in the treatment of angina pectoris have a more
prominent effect on veins and preload than on
vascular tone of coronary arteries. The release of
EDRF in response to thrombin and adenosine
diphosphate in the mammary artery provides
arterial grafts with protective mechanisms against
vasospasm and platelet adhesion and aggre-
gation, which are weak or absent in the vein.
Spasm of coronary bypass grafts has been docu-
mented angiographically173'741. Chronically
implanted human saphenous vein grafts contract
in response to a variety of vasoconstrictor hor-
mones in vitro1751. A decreased endothelial release
of EDRF and PGI2'761 would be associated with
platelet activation and adhesion to the vessel
wall, and this has been implicated in the etiology
of venous graft occlusion'51. Indeed, inhibition
of platelet function does enhance the patency
rate of venous grafts which lack this protective
mechanism'51.
Endothelium-derived contracting factors such as
endothelin dominate EDRF in venous, but not in
arterial grafts'341. In addition, histamine evokes
endothelium-dependent contractions in the saphe-
nous vein, but endothelium-dependent relaxations
in the mammary artery'57'.
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Figure 8 Endothelium-dependent relaxations in response to acetylcholine in
internal mammary arteries (left), saphenous veins (right) obtained from patients
undergoing coronary bypass surgery. Note the much more pronounced response in
arterial than in venous grafts (from ref. 10, by permission). Closed symbols = with
endothelium; open symbols = without endothelium.
Therapeutic implications
Functional changes of the endothelium in athero-
sclerosis and hypertension are at least partly
reversible'77"801. In the aorta of cholesterol-fed
rabbits, treatment with the phosphodiesterase in-
hibitor, dipyramidole, augments or normalizes the
impaired endothelium-dependent relaxations to
acetylcholine and adenosine triphosphate'791. Simi-
larly, non-hypotensive dosages of calcium-channel
antagonists — which suppress the development of
atherosclerosis — partially restore endothelium-de-
pendent relaxations in response to acetylcholine1801.
Eighteen months after cessation of an atherogenic
diet, endothelium-dependent relaxations normalize
in the iliac artery of atherosclerotic primates'771. In
the aorta of rats with salt-induced hypertension,
antihypertensi ve therapy normalizes blood pressure
and restores the blunted endothelium-dependent
relaxations to acetylcholine, adenosine diphosphate
and thrombin (Fig. 6fs\
On the other hand, dietary components which are
known to protect from coronary artery disease and
stroke, improve endothelial function. Populations
with a high dietary fish consumption exhibit a low
death rate from coronary artery disease1811. In the
pig, the development of coronary atherosclerosis
can be delayed by dietary cod-oil supplemen-
tation1821. Dietary supplementation with fish-oil or
its active component, eicosapentaenoic acid, mark-
edly enhances endothelium-dependent relaxations
in response to aggregating platelets and platelet-
derived substances, such as adenosine diphosphate,
serotonin and thrombin, in isolated porcine coron-
ary arteries and augments the release of EDRF
from cultured endothelial cells'83-84'. In addition, fish
oil inhibits platelet function, reduces endothelial
adherence of white blood cells and lowers plasma
lipids'7'8'1. High dietary potassium, which is
associated with a low incidence of stroke, augments
endothelium-dependent relaxations in hypertensive
rats'851.
Platelet inhibitory drugs which inhibit cyclo-
oxygenase (i.e. aspirin) not only block the produc-
tion of thromboxane A2, but also that of vascular
PGI2181. The inability of these drugs to inhibit
EDRF may at least in part explain why even high
dosages did not exert a thrombogenic effect in
patients'8*1. Preserved vascular PGI2 production in
patients under antiplatelet drugs may be important,
since the prostanoid augments the vascular and
antiaggregatory effectsof EDRF1813161. Thus, lower
or alternate daily dosages (i.e. 50-100 mg) are prob-
ably more effective in preventing vascular occlusion
than are the higher dosages used in most trials'8*1.
In disease states with a reduced production of
EDRF, substitution with an EDRF-like drug might
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be promising. Nitroglycerin differs from the en-
dogenous nitrate EDRF in many respects, among
them rapid tolerance and only weak inhibition of
platelet function'871. Whether or not chronic nitro-
glycerin therapy attenuates the response to EDRF
is uncertain'88-891. SIN-1, the active metabolite of the
nitrate molsidomine, has remarkable similarities
with EDRF. It directly activates soluble guanylate
cyclase, it induces vascular relaxation with a
potency similar to that of EDRF, inhibits platelet
function, and tolerance does not seem to occur dur-
ing chronic therapy188-90"1. Long-term studies are
needed to assess possible vascular protective effects
of this EDRF-like nitrate.
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